BAXTER INTERNATIONAL INC acquired PerClot Polysaccharide Hemostatic System (assets, from CryoLife, Inc.) for $25 million upfront cash plus up to $36 million of additional contingent consideration (acquisition-date fair value $28 million), a transaction completed in July 2021, structured as all cash (with contingent consideration). The deal was a Asset purchase.
PerClot Polysaccharide Hemostatic System (assets, from CryoLife, Inc.) operates in BioSurgery / hemostats, is based in Acquired from CryoLife, Inc. (Kennesaw, Georgia, USA); distribution rights for the U.S. and specified ex-US territories. PerClot Polysaccharide Hemostatic System is an absorbable powder hemostat; Baxter acquired certain related assets, including distribution rights for the U.S. and specified territories outside the U.S., from CryoLife, Inc.
Adds a complementary absorbable hemostat to Baxter's biosurgery and advanced surgery portfolio.
Complementary absorbable hemostat extending Baxter's BioSurgery / Advanced Surgery franchise. Integrated into Baxter's Advanced Surgery business
On July 29, 2021, we acquired certain assets related to PerClot Polysaccharide Hemostatic System (PerClot), including distribution rights for the U.S. and specified territories outside of the U.S., from CryoLife, Inc. for an upfront purchase price of $25 million and the potential for additional cash consideration of up to $36 million, which had an acquisition-date fair value of $28 million.Baxter FY2021 10-K, Acquisitions note
Advisory firms were not disclosed for this transaction.